Chronic Lymphocytic Leukemia
We include a report of this small group of patients here because we have observed apparent major responses in chronic lymphocytic leukemia (CLL) associated with and apparently caused by (the use of) BRM therapy. Over the last four years, we treated five patients who were not taking any conventional treatment. All patients are still alive, have excellent quality of life and have no complaints. We want to present here two case reports of patients who responded very well with normalization of elevated lymphocyte count, and a third case of significant lymphocyte drop followed by stabilization at the lower level.
Caucasian male, 69-years-old, previous heavy smoker presented in 03/26/99 with abdominal pain, weakness, insomnia, depression, constipation and enlarged spleen caused by chronic lymphocytic leukemia. At the time the patient came to our Center, he was not receiving any treatment for his leukemia. CT scan of abdomen demonstrated splenomegaly – spleen measured 132 mm. WBC was 55.4 thousand/UL (nl 4.8-10 thousand); B2M (cancer biomarker) was 2.4 mg/L (nl 0-2).
Initial BRM therapy consisted of antioxidants (vitamin E, selenium, OPC, ascorbic acid mixture, vitamin A), gonadal hormone replacement (Premarin, Provera, testosterone gel, DHEA, pregnenolone), and other supplements which usually increase production of natural killer cells; i.e., melatonin, MacroForce, whey protein fraction (Immunocal), cat’s claw, multiple digestive enzymes, bromocriptine (Parlodel), omega 3-fatty acids, and MGN-3.
During subsequent visits, BRM’s were changed based on assessment of subjective and objective status.
The treatment and outcome of patient are summarized Table 1.
DATE WBC B2M Treatment
(4.8 -10) (0 -2)
03/26/98 55.4 Start BRM therapy
06/01/98 44.6 2.4
11/03/98 Stopped BRM’s “sick at stomach”
11/11/98 56.5 Restart BRM therapy
12/30/98 Start Parlodel 1.25 mg bid
01/14/99 35.8 2.8
02/15/99 Stopped Parlodel after mastodynia resolved
03/22/99 51.3 (Stopped Provera this day)
05/25/99 22.5 1.0
07/01/99 12.6 1.2
Black female, age 55 years, presented 04/23/96 with aches in neck, back, legs, extreme weakness, hoarseness, loss of voice, anxiety, anorexia, constipation. Malignant lymphoma, follicular predominantly cleaved small cell type, was diagnosed in March 1993. After an initial two cycles of chemotherapy, patient believed herself unable to tolerate chemotherapy both emotionally and physically, and she absolutely refused chemotherapy because of its previous morbidity. Unfortunately, she was increasingly troubled by diffuse bony aches which were rather typical for bone marrow involvement. She decided to come in our Cancer Center for a trial on alternative medicine.
We told this patient that alternative medication was not likely to create a remission in her current condition which was that of rather advanced bone marrow progression, but that we could try to reduce the decline in immune resistance to cancer which occurs with aging with a bioresponse modifier regimen. BRM’s used included Premarin, Provera, methyl testosterone, bromocriptine (Parlodel), vitamin E, vitamin C, selenium, beta carotene, and cat’s claw.
The treatment and outcome of patient are summarized Table 2
Date WBC lymph % Treatment
(4.8 – 10) (15-41)
06/30/95 191,400 96 clorambucil and prednisone
07/03/95 131,700 96 repeat chemo; no further chemotherapy
07/06/95 78.1 89
08/21/95 4.1 33
09/28/95 3.6 44
10/24/95 9.2 63.9
12/14/95 32.7 83.7
12/27/95 40.6 83.7
01/22/96 61.4 90
04/23/96 39.3 87.4 start BRM regimen
06/10/96 27.5 81.4
08/08/96 16.6 71.3
08/12/96 14.9 77
10/07/96 6.2 55
12/02/96 4.5 43
03/03/97 4.5 38
04/28/97 4.8 37.6
Author’s Comment: This patient’s greatly elevated WBC completely normalized with substantial improvement in quality of life. Virtually all chemotherapy for this condition involves agents which result in increased genetic instability. The natural history of CLL is several years of stable count on chemotherapy followed by a fulminant progression due to dedifferentiation of the malignancy to a more malignant form. Any modality capable of inducing normalization of counts which is non toxic and which does not involve agents which destabilize the genome is almost certainly capable of extending overall survival. The question arises from this case: when if ever should BRM by (be) primary standard of care followed by conventional chemotherapy for BRM failure?
Caucasian female, age 71 years, presented 07/05/96 with known CLL since 1981, malaise, and a rising white count. Patient complained of a very low energy level and psychological depression. For the last sixteen years she had done very well. She continued to take daily Cytoxan 50 mg, one tablet five times a week. She had not had any systemic symptoms during this period. Her white count, however, had risen to 31,500 and her quality of life had dropped markedly. CT scan of the chest and abdomen demonstrated numerous axillary nodes present greater on the right than on the left. Most of these measured less than a cm., with 1.5 cm. being the maximum diameter. The spleen was enlarged.
We suggested BRM’s consisting of ascorbic acid mixture, vitamin E, selenium, cimetidine, Premarin, natural progesterone, and bromocriptine. She tolerated BRM therapy reasonably well except for nausea and relative intolerance to bromocriptine. Since BRM’s, self-perceived health was clearly better. Energy improved. Mood was generally improved. Depression was lessened. She stopped taking ascorbic acid mixture, attributing sore mouth to this agent even after reducing her dose. WBC dropped to 24120 during first month. During follow ups we changed BRM’s according to her subjective and objective data.
Patient takes cat’s claw, OPC’s, Immunocal, DHEA, pregnenolone, multiple enzymes, MacroForce, MSM, HGH, and hydrazine sulfate.
The treatment and outcome of patient are summarized Table 3
Date WBC % lymphs Treatment
04/05/96 18.85 67.7
07/05/96 32.1 start BRM
07/09/96 31.5 85.0
11/04/96 21.3 80.4
12/04/96 17.9 80.2
01/14/97 start HGH 12 days
01/21/97 22.1 80.1
01/21/97 stop HGH (WBC elevation)
02/26/97 23.69 88.0
05/12/97 19.2 80.3
05/13/97 start hydrazine sulfate
06/24/97 24.8 85.2
06/24/97 stop hydrazine sulfate (WBC elevation)
08/25/97 22.39 73.7
09/09/97 24.1 84.6
10/27/97 22.9 82.9
01/06/98 24.6 83.3
02/25/98 22.73 7 2.0
08/26/98 28.44 74.8
06/22/99 23.4 84.4
Author’s Comment: Patient’s disease, as assessed by lymphocyte count, initially declined and then remained very stable with white count running 20,000 to 24,000. Chest X-ray 02/24/99 was normal. Quality of life is good. As natural history of disease is typically a gradual rise in WBC, a positive response from BRM appears to be present.